Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs for Dermatomyositis have a 60% phase transition success ...

Mankind Pharma has entered into a partnership with Innovent Biologics for licensing and commercialising Sintilimab for cancer in India.

CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Acute Coronary Syndrome.

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...

PF-07976016 is under development for the treatment of obesity. It is administered as oral solution and oral suspension. The drug candidate acts by targeting gastric inhibitory peptide (GIPR).

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.